<qa>  What is the primary endpoint of the trial?This is an open-label randomized trial in patients with HER2-negative metastatic breast cancer. Patients will be treated with either taxane alone investigator choice of paclitaxel or docetaxel or taxane with bavituximab. Paclitaxel will be given 3 of 4 weeks, docetaxel will be given once every 3 weeks, and bavituximab will be given weekly. All therapy will continue until disease progression, toxicity, withdrawal or consent, investigator decision, or study termination. Efficacy overall response rate is the primary endpoint while safety is the secondary endpoint. 